News 23andMe doses first patient in ph2a anti-tumour monotherapy Additionally, the company will be making investor presentations today and next week.
News Merck drops last phase 3 Keytruda trial in prostate cancer KEYNOTE-641 showed no benefit when added to Xtandi for castration-resistant prostate cancer.
News OCI-led CAR-T leukaemia therapy receives €2.5m from EIC New therapy for a mainly paediatric leukaemia won't require extraction of patient's own cells.
News Forget Merck, now Pfizer is said to be after Seagen Rumour of negotiations comes as Pfizer is facing a steep patent cliff in the next few years.
News J&J gets restricted label for PARP drug Akeega in EU Drug is backed for BRCA+ prostate cancer patients only, a narrower group than rival Lynparza.
News Redx joins with Jounce to create cancer, fibrosis biotech Merger is announced after Jounce said it will slash staff and seek partners for its programmes.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
